Correlation Between Syndax Pharmaceuticals and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Syndax Pharmaceuticals and SAB Biotherapeutics, you can compare the effects of market volatilities on Syndax Pharmaceuticals and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and SAB Biotherapeutics.

Diversification Opportunities for Syndax Pharmaceuticals and SAB Biotherapeutics

-0.1

Correlation Coefficient

Syndax Pharmaceuticals  SAB Biotherapeutics

Good diversification

The 3 months correlation between Syndax and SAB is -0.1. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Syndax Pharmaceuticals and SAB Biotherapeutics

Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to generate 2.36 times less return on investment than SAB Biotherapeutics. But when comparing it to its historical volatility, Syndax Pharmaceuticals is 6.6 times less risky than SAB Biotherapeutics. It trades about 0.02 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  9.00  in SAB Biotherapeutics on December 26, 2024 and sell it today you would lose (6.31) from holding SAB Biotherapeutics or give up 70.11% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	91.8%
Values	Daily Returns

Syndax Pharmaceuticals  vs.  SAB Biotherapeutics

Syndax Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Syndax Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong fundamental indicators, Syndax Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

SAB Biotherapeutics

Risk-Adjusted Performance

Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly uncertain basic indicators, SAB Biotherapeutics may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Syndax Pharmaceuticals and SAB Biotherapeutics

The main advantage of trading using opposite Syndax Pharmaceuticals and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Syndax Pharmaceuticals and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.